Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 3/20 | 0.41 |
| ▸ | CDK8 | P49336 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.39 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20474756 | 0.81 | JAK2 (0.38) | OPRK1 | |
| SCHEMBL20474702 | 0.77 | ACACB (0.47) | ACACBCCNCCDK8CYP46A1 | |
| SCHEMBL20354142 | 0.77 | ACACB (0.46) | ACACBOPRK1 | |
| SCHEMBL18487129 | 0.77 | ACACB (0.46) | ACACBOPRK1 | |
| SCHEMBL29414900 | 0.77 | ACACB (0.46) | ACACBOPRK1 | |
| SCHEMBL20354188 | 0.75 | ACACB (0.45) | ACACBOPRK1 | |
| SCHEMBL30748905 | 0.75 | ACACB (0.45) | ACACBOPRK1 | |
| SCHEMBL20474710 | 0.74 | ACACB (0.46) | ACACBCCNCCDK8CYP46A1 | |
| SCHEMBL20354209 | 0.73 | ACACB (0.52) | ACACBOPRK1 | |
| SCHEMBL24240549 | 0.71 | ACACB (0.50) | ACACBOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3585775-B1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2022-04-06 | — | — | EP | disclosed |
| US-10392366-B2 | Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2019-08-27 | — | — | US | disclosed |
| WO-2018153849-A1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2018-08-30 | — | — | WO | disclosed |
| US-20180237419-A1 | AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392366-B2 | Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | GPR119, GPR39, GPR139 | ACACB 907/4885CCNC 4703/4885CDK8 4738/4885 |
| US-20180237419-A1 | AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GIPR, GPR39 | ACACB 1569/4885CCNC 4650/4885CDK8 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.